Influence of smoking in the glutathione-S-transferase M1 deficiency--associated risk for squamous cell carcinoma of the bladder in schistosomiasis patients in Egypt. by Lafuente, A. et al.
British Journal of Cancer (1996) 74, 836-838
©C) 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
Influence of smoking in the glutathione-S-transferase Ml deficiency-
associated risk for squamous cell carcinoma of the bladder in
schistosomiasis patients in Egypt
A Lafuentel, MM Zakahary2, MAA El-Aziz3, C Ascaso4, MJ Lafuente5, M Trias5 and P
Carretero6
'Institut de Salut Pu'blica, University ofBarcelona, Barcelona, Spain; Departments of2Biochemistry and 3Urology, Faculty of
Medicine, Assiut University, Assiut, Egypt; Departments of 4Epidemiology and Biostatistics, 'Surgery and 6Urology, Hospital
Clinic, University ofBarcelona, CIVillarroel 170, 08036 Barcelona, Spain.
Summary In this study we show an effect of the glutathione-S-transferase MI (GSTM1) null phenotype on
the risk for squamous cell carcinoma (SCC) of the bladder among male smokers in Egypt, with an adjusted
odds ratio of 4.8 (95% confidence interval:1.06-21.77). However, no overall effect of the GSTM1 null
phenotype on the risk for bladder SCC was observed.
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Carcinoma of the urinary bladder is the most common
malignancy in many tropical and subtropical countries. There
is a well-documented association with chronic urinary
schistosomal infection, resulting in squamous cell carcinoma
of the bladder (SCC), which is a major cause of morbidity
and mortality in the endemic areas (IARC, 1994).
Furthermore, foreign compounds from tobacco smoking
may be involved in up to 50% of bladder cancers
(transitional cell carcinoma, TCC) in western populations
(Cole et al., 1971), through metabolic intermediates, most of
them probably oxidised metabolites from N-nitroso-com-
pounds, aromatic amines and polycyclic aromatic hydro-
carbons (IARC, 1986; Wynder and Goldsmith, 1977).
Glutathione-S-transferase Ml (GSTM1) detoxifies various
carcinogenic electrophiles including epoxides. A protective
role against neoplasias associated with smoking has, there-
fore, been attributed to it. GSTM 1 has polymorphic
expression and about half the population in various racial
groups lack it (Hussey et al., 1986). Indeed, a greater
susceptibility to lung (Seidegard et al., 1990) and larynx
cancer (Lafuente et al., 1933) has been shown among smokers
lacking GSTM1. Susceptibility to bladder cancer has also
been studied, although only transitional cell carcinoma has
been considered (Zhong et al., 1993; Lafuente et al., 1993;
Bell et al., 1993; Daly et al., 1993; Brockmoller et al., 1994;
Lin et al., 1994). Some of these studies found a protective
effect of GSTM1 in bladder cancer (Table I).
We, therefore, designed a study to determine whether
GSTM1 deficiency may confer susceptibility to the squamous
cell carcinoma of the bladder associated with schistosomiasis.
Our hypothesis is based on the antioxidant properties of this
isoenzyme, which is able to metabolise the hydroperoxides of
DNA that may be produced in chronic inflammation
(Ketterer and Meyer, 1989; Lafuente et al., 1995). Although
SCC of the bladder is not known to be related to smoking,
we have attempted to assess the influence of the smoking
habit on this carcinogenic process, given the role of the GST
system in the metabolism of the toxic products of tobacco.
Materials and methods
Eighty bladder SCC patients were recruited at the Urology
Department of the University of Assiut, Egypt, between 1993
and 1994; 66 patients were men (mean age 45.2+6.5 years)
and 14 were women (mean age 41.0+7 years). All had
histologically proven SCC of the bladder and none had
received prior chemotherapy or radiotherapy. All tumours
were deeply invasive (pT3 and pT4).
Seventy unrelated control individuals (C) without clinical
or histological evidence of cancer or inflammatory pathology
were recruited from employees at the same university (55
men, mean age 43.0+4.2 years and 15 women, mean age
37.0+7 years). Fifty patients with schistosomiasis cystitis
(SC) were studied as a separate group of which 49 were male
(mean age 36.5 +7 years).
Smoking histories were collected by clinicians during the
preoperatory visit, calculating 1 pack- year unit as the
number of packs of cigarettes smoked per day x number of
years of smoking. A total of 60% of smokers in the SCC
group and 83% in the control group were heavy smokers
(more than 13 pack -years).
The study of the group of women was performed
separately and the results are included for descriptive
purposes only, since they show a different phenotype
distribution from that in men (Seidegard et al., 1990); they
do not smoke and for social reasons they are rarely visited
for the treatment of schistosomiasis.
Blood samples (2 ml) were obtained from all subjects,
frozen at -20°C and sent to Spain for analysis.
Leucocytic GSTM1 was measured in whole blood samples
with an enzyme-linked immunoassay (ELISA) using affinity-
purified rabbit polyclonal antibody to human GSTM1
(Mukit, Biotrin, Dublin, Ireland). Haemolysed blood (50 ul)
was mixed with 125 ,l phosphate-buffered saline (PBS)
including 1% bovine serum albumin and 25 Ml Triton X-100.
The remaining procedure was as specified in the Mukit
technical bulletin, with the modification introduced by
Brockm6ller et al. (1993) for the quantitative calibration of
all assays: one batch of electrophoretically pure GSTM1 class
protein (from Biotrin) was added to one batch of venous
blood (in PBS, 1: 1) from a GSTM1-deficient individual.
Standard curves were plotted between 0.010 and 50 jug ml-'
in whole blood. Individuals with enzyme levels below
1 jug ml- 1 of blood were considered to be deficient in
GSTM1. The mean of GSTM1 cross-reacting proteins for
negative individuals was 0.117 ,ug ml-' of blood.
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Table I Epidemiological studies on GSTM1 deficiency as a bladder cancer risk factor
Bladder/Controls Histological Smoking- Ethnic
cancer OR (95% CI) P-value Methods type dependent risk group Country (Reference)
39%b 52% 1.7 (1.1-2.5) 0.007 G TCC Yes Blacks and USA (Bell, 1993)
whites 33.3%c 54.6%c 2.41 (1.18-4.93) 0.007 Ph TCC Yes Whites Spain (Lafuente, 1993)
15.1% 40.4% 3.81 (1.53-9.34) 0.0002 G TCC None England (Daly, 1993)
59.8% 58.2% 0.84 (0.50-1.40) NS G Not studied England (Zhong, 1993)
40.9% 49.3% 1.40 (1.02-1.92) 0.017 G&Ph TCC None Whites Germany (Brockmoller, 1994)
SCC (4 cases)
44.7% 51.1% 1.40 (0.94-2.10) NS G Not studied Mixed USA (Lin, 1994)
30.3% 58.3%c 3.2 (0.94-11.32) 0.03 Ph SCC Yes Egyptians This study
aMethod: genotyping (G), phenotyping (Ph). bPercentage ofGSTM1 active individuals. cOnly smokers.
Table II Characteristics of the male population and corresponding crude odds ratio and 95% confidence intervals (CIs)
for bladder SCC risk
Bladder Control Chi-
cancer (SCC) (C) square P-value ORa 95% CI
Negative
GSTM1 39/66 (0590)b 28/55 (0.509) 0.81 0.36 1.39 0.64-3.06
Age>45 years 30/66 (0.454) 17/55 (0.309) 5.25 0.02 2.34 1.06-5.21
Smokers 33/66 (0.500) 24/55 (0.436) 0.49 0.48 1.29 0.59-2.83
aCrude odds ratio in SCC group vs control individuals in the respective stratum. bNumber/total number (%).
For statistical analysis, univariate analysis was performed
using chi-square with continuity correction. This enabled us
to establish categories for the continuous variables as follows:
age (>45 years vs <45 years), smoking habit (smokeers vs
non-smokers). The expression of the GSTM1 phenotype was
considered as the other epidemiological variable. Stepwise
logistic regression was also used to assess the independent
contribution of variables. P-values below 0.05 were
considered to be statistically significant.
Table III Adjusted odds ratios and 95% confidence interval about
bladder SCC risk in male group
ORa 95% CI
Negative GSTM1 0.72 0.26- 1.97
Age (>45 years) 2.38 1.10-5.15
Smoking 0.45 0.14-1.38
Negative GSTM1 and 4.80 1.06-21.77
smoking
aAdjusted odds ratio in SCC group vs control individuals in the
respective stiratum.
Results
Our data show a bimodal distribution of GSTM1 content,
positioning the antimode at 1 Mg ml-1, thus confirming the
previously established antimode described by Brockm6ller et
al. (1993). The mean GSTM1 content was 3.3+0.9, 3.1+ 1.3
and 3.8 +0.3 ,ug ml-' of blood for positive controls, SCC and
SC cases respectively.
Table II displays the characteristics of the male population
and the crude odds ratio for the three variables studied:
GSTM1 phenotype, age and smoking habit, showing an
association between the SCC risk and age (more than 45
years old). The frequency of GSTM1-negative individuals
was higher in the subgroup of SCC male smokers (69% vs
41%). When adjusted odds ratios were calculated, an
association among smoking habit, GSTM1 phenotype and
SCC risk was evident, indicating that smokers with this
metabolic deficiency have a 4.8-fold risk of developing these
cancers (1.06-21.77 CI) (Table III). Stratification by smoking
habit shows that this association was mostly attributable to
the high smoking exposure (> 13 pack-years) giving 80% of
negative phenotypes in the SCC group vs 40% in the control
group, and a crude odds ratio of 12.3 (P=0.007). When all
male cases, smokers and non-smokers, were considered,
frequencies of negative GSTM1 phenotypes were similar in
the groups studied; SCC (59%) and C (50.9%) with no
overall effect of the GSTM1 null phenotype on the risk for
bladder SCC. Stratification based on tumour characteristics
showed the null phenotype to be more common among
patients with poorly differentiated lesions (WHO tumour
grade G-3 65.8%, as compared with G-2 50% and G-1
33.3%) but these differences were not statistically significant.
In the group of male schistosomiasis cystitis patients (SC)
frequencies of negative GSTM1 phenotypes were similar
(57.1% vs 50.9%) and also exhibited a high proportion of
negative patients among smokers (66.6%).
Females, in general, show a lower proportion of null
phenotypes than males (42% SCC vs 46% control), but in
this case differences with respect to smoking cannot be
demonstrated since all the women were non-smokers.
No difference in GSTM1 content in positive individuals
was found between any of the subgroups established.
Discussion
In a recent review, Badawi et al. (1992) stress the
multifactorial aetiology of bladder SCC, including the
promoting effect of chronic infectious disease. Our results
suggest that tobacco smoking may also increase the risk of
this malignancy in GSTM1-negative schistosomiasis patients.
An effect of smoking on the GSTM1 deficiency-associated
risk of cancer has been described in relation to other
squamous cell carcinomas such as SCC of lung (Hayashi,
1992) and other tobacco-dependent neoplasms such as TCC
of the bladder (Lafuente et al., 1993; Bell et al., 1993) (Table
I). The coincidence of parasitic genotoxins, tobacco
toxicants, greater age (as a non-specific factor) and an
increase in oxidative capacity caused by schistosomiasis may
favour the development of the neoplasm. In this regard,
high rates of p53 gene mutations, which are more frequent
in GSTM1-negative individuals (Ryberg et al., 1994) have
recently been reported in SCC bladder cancer, which may be
related to cigarette smoking and schistosomiasis (Habuchi etGxutahoe-S-ransferase MI and blder cancer in Egypt
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al.. 1993). In such circumstances. the protection of GSTM1
may be essential because they are predominantly distributed
in bladder epithelial cells, providing protection against DNA
damage induced by reactive oxygen species as well as against
carcinogens from tobacco smoke (Singh et al., 1994). The
possible synergism between schistosomiasis, smoking habit
and the absence of the GSTM1 enzyme for SCC may be
similar to that described for asbestosis, smoking habit and
GSTM1 deficiency in lung cancer (Anttila et al., 1995).
This is the first study of an Egyptian population With
reference to the GSTM1 phenotype polymorphism. The
distribution of the positive phenotype does not differ from
that found in other ethnic populations elsewhere (Lin et al..
1994). Attention is drawn to a pharmacogenetic study of the
pattern of hydroxylation of debrisoquine (P4501ID6) in
Egypt published some years ago (Mahgoub et al., 1979).
reporting that the incidence of poor metabolisers in that
population was lower (1%) than that found among British
subjects (6%). The present study reveals an increased risk in
that (Egyptian) population. since a more active oxidation
would increase toxicity of nitroso-compounds and other
toxicants coming from parasites or tobacco smoke.
Combined genetic studies on cytochrome P450 and GSTM1
polymorphisms are now needed.
Tobacco smoking has been rare in most parts of Africa
where bladder cancer associated with schistosomiasis infec-
tion is common and so it has been little studied. The
association between smoking habit, GSTM1 phenotype and
the risk of bladder SCC first reported here. calls for further
studies on the influence of this habit in the aetiopathogenesis
of this malignancy. On the basis of our results. it appears
that the antischistosomal drug, Oltipraz. may be doubly
beneficial because it is not only anti-parasitic but also an
inducer of phase II enzymes such as the glutathione
transferases (Kensler et al.. 1992).
Abbreviations
DNA. deoxyribonucleic acid: GSTM1. glutathione-S-transferase
Mu; SCC. squamous cell carcinoma; SC. schistosomiasis cystitis;
TCC. transitional cell carcinoma.
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